Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

被引：41

作者：

Nurwidya, Fariz ^{[1
]}

Takahashi, Fumiyuki ^{[1
]}

Murakami, Akiko ^{[1
]}

Kobayashi, Isao ^{[1
]}

Kato, Motoyasu ^{[1
]}

Shukuya, Takehito ^{[1
]}

Tajima, Ken ^{[1
]}

Shimada, Naoko ^{[1
]}

Takahashi, Kazuhisa ^{[1
]}

机构：

[1] Juntendo Univ, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138421, Japan

来源：

RESPIRATORY INVESTIGATION | 2014年 / 52卷 / 02期

关键词：

Acquired resistance; Epidermal growth factor receptor (EGFR); Non-small cell lung cancer (NSCLC); Tyrosine kinase inhibitors;

D O I：

10.1016/j.resinv.2013.07.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Activation of epidermal growth factor receptor (EGFR) triggers anti-apoptotic signaling, proliferation, angiogenesis, invasion, metastasis, and drug resistance, which leads to development and progression of human epithelial cancers, including non-small cell lung cancer (NSCLC). Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. This review will discuss the biology of receptor tyrosine kinase inhibition and focus on the molecular mechanisms of acquired resistance to tyrosine kinase inhibitors of EGFR-mutant NSCLC. (C) 2013 The Japanese Respiratory Socity. Published by Elsevier B.V. All rights reserved.

引用

页码：82 / 91

页数：10

共 113 条

[91] Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer [J].

Takeuchi, Shinji ;

Wang, Wei ;

Li, Qi ;

Yamada, Tadaaki ;

Kita, Kenji ;

Donev, Ivan S. ;

Nakamura, Takahiro ;

Matsumoto, Kunio ;

Shimizu, Eiji ;

Nishioka, Yasuhiko ;

Sone, Saburo ;

Nakagawa, Takayuki ;

Uenaka, Toshimitsu ;

Yano, Seiji .

AMERICAN JOURNAL OF PATHOLOGY, 2012, 181 (03) :1034-1043

[92] HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation [J].

Takezawa, Ken ;

Pirazzoli, Valentina ;

Arcila, Maria E. ;

Nebhan, Caroline A. ;

Song, Xiaoling ;

de Stanchina, Elisa ;

Ohashi, Kadoaki ;

Janjigian, Yelena Y. ;

Spitzler, Paula J. ;

Melnick, Mary Ann ;

Riely, Greg J. ;

Kris, Mark G. ;

Miller, Vincent A. ;

Ladanyi, Marc ;

Politi, Katerina ;

Pao, William .

CANCER DISCOVERY, 2012, 2 (10) :922-933

[93] Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer [J].

Tang, Z. ;

Du, R. ;

Jiang, S. ;

Wu, C. ;

Barkauskas, D. S. ;

Richey, J. ;

Molter, J. ;

Lam, M. ;

Flask, C. ;

Gerson, S. ;

Dowlati, A. ;

Liu, L. ;

Lee, Z. ;

Halmos, B. ;

Wang, Y. ;

Kern, J. A. ;

Ma, P. C. .

BRITISH JOURNAL OF CANCER, 2008, 99 (06) :911-922

[94] Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC [J].

Turke, Alexa B. ;

Zejnullahu, Kreshnik ;

Wu, Yi-Long ;

Song, Youngchul ;

Dias-Santagata, Dora ;

Lifshits, Eugene ;

Toschi, Luca ;

Rogers, Andrew ;

Mok, Tony ;

Sequist, Lecia ;

Lindeman, Neal I. ;

Murphy, Carly ;

Akhavanfard, Sara ;

Yeap, Beow Y. ;

Xiao, Yun ;

Capelletti, Marzia ;

Iafrate, A. John ;

Lee, Charles ;

Christensen, James G. ;

Engelman, Jeffrey A. ;

Jaenne, Pasi A. .

CANCER CELL, 2010, 17 (01) :77-88

[95] Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer [J].

Usuda, J. ;

Ohira, T. ;

Suga, Y. ;

Oikawa, T. ;

Ichinose, S. ;

Inoue, T. ;

Ohtani, K. ;

Maehara, S. ;

Imai, K. ;

Kubota, M. ;

Tsunoda, Y. ;

Tsutsui, H. ;

Furukawa, K. ;

Okunaka, T. ;

Sugimoto, Y. ;

Kato, H. .

LUNG CANCER, 2007, 58 (02) :296-299

[96] Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic [J].

Voulgari, Angeliki ;

Pintzas, Alexander .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1796 (02) :75-90

[97] Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer [J].

Wang, Wei ;

Li, Qi ;

Takeuchi, Shinji ;

Yamada, Tadaaki ;

Koizumi, Hitomi ;

Nakamura, Takahiro ;

Matsumoto, Kunio ;

Mukaida, Naofumi ;

Nishioka, Yasuhiko ;

Sone, Saburo ;

Nakagawa, Takayuki ;

Uenaka, Toshimitsu ;

Yano, Seiji .

CLINICAL CANCER RESEARCH, 2012, 18 (06) :1663-1671

[98] Functional selectivity of EGF family peptide growth factors: Implications for cancer [J].

Wilson, Kristy J. ;

Gilmore, Jennifer L. ;

Foley, John ;

Lemmon, Mark A. ;

Riese, David J., II .

PHARMACOLOGY & THERAPEUTICS, 2009, 122 (01) :1-8

[99] Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines [J].

Witta, SE ;

Gemmill, RM ;

Hirsch, FR ;

Coldren, CD ;

Hedman, K ;

Ravdel, L ;

Helfrich, B ;

Dziadziuszko, R ;

Chan, DC ;

Sugita, M ;

Chan, Z ;

Baron, A ;

Franklin, W ;

Drabkin, HA ;

Girard, L ;

Gazdar, AF ;

Minna, JD ;

Bunn, PA .

CANCER RESEARCH, 2006, 66 (02) :944-950

[100] Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer [J].

Wu, Jenn-Yu ;

Yang, Chih-Hsin ;

Hsu, Ya-Chieh ;

Yu, Chong-Jen ;

Chang, Shih-Han ;

Shih, Jin-Yuan ;

Yang, Pan-Chyr .

CLINICAL LUNG CANCER, 2010, 11 (04) :257-263

← 3 4 5 6 7 8 9 10 11 12 →